Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus
Arthritis Rheum
.
2004 Aug;50(8):2415-22.
doi: 10.1002/art.20353.
Authors
Joel Schiffenbauer
1
,
Bevra Hahn
,
Michael H Weisman
,
Lee S Simon
Affiliation
1
Center for Drug Evaluation and Research, FDA, Rockville, Maryland 20850, USA. schiffenbaue@cder.fda.gov
PMID:
15334452
DOI:
10.1002/art.20353
No abstract available
MeSH terms
Biomarkers*
Clinical Trials as Topic*
Humans
Lupus Erythematosus, Systemic / drug therapy*
Outcome Assessment, Health Care
Research Design*
Substances
Biomarkers